---
title: "Sunshine Biopharma, Inc. (SBFM.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/SBFM.US.md"
symbol: "SBFM.US"
name: "Sunshine Biopharma, Inc."
industry: "Biotechnology"
datetime: "2026-05-19T09:39:26.902Z"
locales:
  - [en](https://longbridge.com/en/quote/SBFM.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/SBFM.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/SBFM.US.md)
---

# Sunshine Biopharma, Inc. (SBFM.US)

## Company Overview

Sunshine Biopharma, Inc. operates as a pharmaceutical company that engages in the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [unshinebiopharma.com](https://unshinebiopharma.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:12.000Z

**Overall: C (0.47)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 179 / 387 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -2.05% |  |
| Net Profit YoY | -20.07% |  |
| P/B Ratio | 0.12 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 2502031.95 |  |
| Revenue | 35493315.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -27.33% | E |
| Profit Margin | -17.02% | D |
| Gross Margin | 26.96% | C |
| Revenue YoY | -2.05% | D |
| Net Profit YoY | -20.07% | D |
| Total Assets YoY | -4.31% | D |
| Net Assets YoY | -5.22% | D |
| Cash Flow Margin | 94.51% | C |
| OCF YoY | -2.05% | D |
| Turnover | 1.24 | A |
| Gearing Ratio | 22.96% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Sunshine Biopharma, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-2.05%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-20.07%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "0.12",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "2502031.95",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "35493315.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-27.33%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-17.02%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "26.96%",
          "rating": "C"
        },
        {
          "name": "Revenue YoY",
          "value": "-2.05%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "-20.07%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "-4.31%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "-5.22%",
          "rating": "D"
        },
        {
          "name": "Cash Flow Margin",
          "value": "94.51%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "-2.05%",
          "rating": "D"
        },
        {
          "name": "Turnover",
          "value": "1.24",
          "rating": "A"
        },
        {
          "name": "Gearing Ratio",
          "value": "22.96%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.41 | 124/387 | - | - | - |
| PB | 0.12 | 6/387 | 0.30 | 0.26 | 0.23 |
| PS (TTM) | 0.07 | 4/387 | 0.19 | 0.18 | 0.15 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Vaxart (VXRT.US) | A | A | A | C | B | A |
| 05 | Spero Therap (SPRO.US) | A | A | B | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-18T04:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 0.51 |
| Highest Target | 5.60 |
| Lowest Target | 5.60 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/SBFM.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/SBFM.US/norm.md)
- [Related News](https://longbridge.com/en/quote/SBFM.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/SBFM.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**